Moderna (NASDAQ: MRNA) and Takeda Pharmaceutical (NYSE: TAK) issued a joint statement today to say there is no evidence that the two deaths in Japan were related to the administration of the vaccine.

Two companies conducted a review that showed “the rare presence of stainless steel particles in the Moderna COVID-19 vaccine.” However, the presence “does not pose an undue risk to patient safety and it does not adversely affect the benefit/risk profile of the product.”

The steel element is classified as Grade 316 - a high grade of stainless steel commonly used in manufacturing and in food processing.

“Metallic particles of this size injected into a muscle may result in a local reaction, but are unlikely to result in other adverse reactions beyond the local site of the injection. Stainless steel is routinely used in heart valves, joint replacements and metal sutures and staples. As such, it is not expected that injection of the particles identified in these lots in Japan would result in increased medical risk,” two companies added.

So far, the relationship between the administered Moderna vaccines and two deaths is considered to be “coincidental.” Takeda is distributing the vaccine.

This statement comes just hours after Japan found black particles in a MRNA vaccine, which forced the local authorities to put the rest of the patch on hold.

Last week, Japan put over 1.6 million doses of Moderna vaccines on hold after identifying contamination in some of the supply.